Timo Oosenbrug

6PUBLICATIONS
24CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Medical devicesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 19, 2026
USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production.

|Feb 21, 2024
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.

Xin Lei, Daniël C de Groot, Marij J P Welters

|Feb 14, 2022
RNA sensing via the RIG-I-like receptor LGP2 is essential for the induction of a type I IFN response in ADAR1 deficiency.

Jorn E Stok, Timo Oosenbrug, Laurens R Ter Haar

|Aug 18, 2021
Induction of Robust Type I Interferon Levels by Oncolytic Reovirus Requires Both Viral Replication and Interferon-α/β Receptor Signaling.

Timo Oosenbrug, Diana J M van den Wollenberg, Eline W Duits

|Aug 16, 2020
An alternative model for type I interferon induction downstream of human TLR2.

Timo Oosenbrug, Michel J van de Graaff, Mariëlle C Haks

|Jun 09, 2020
Conditionally Controlling Human TLR2 Activity via Trans-Cyclooctene Caged Ligands.

Michel J van de Graaff, Timo Oosenbrug, Mikkel H S Marqvorsen

Pageof 1

Frequent Collaborators

3 joint publications

Annemarthe van der Veen

2 joint publications

Sander van Kasteren

1 joint publications

Mark A R de Geus

1 joint publications

Maaike E Ressing